OPQ- Drug Sampling and Testing Program
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $250,000 to $700,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- Points of contact
-
- CDER Acquisition Liaison cderacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is forecasting a new requirement for the OPQ-Drug Sampling and Testing Program, with an estimated solicitation release date of February 1, 2026, and an estimated award date of August 1, 2026. This procurement falls under the Drugs and Druggists' Sundries Merchant Wholesalers NAICS category (424210) and will involve drug sampling and testing services to support FDA operations. No set-aside provisions have been designated for this opportunity.
The estimated award value ranges from $250,000 to $700,000, providing a substantial budget for the selected contractor to execute the sampling and testing program. Interested vendors should direct inquiries to the FDA's Acquisition Liaison at cderacquisitions@fda.hhs.gov, which serves as the primary point of contact for this forecasted opportunity. The procurement was posted on January 31, 2026, allowing potential bidders advance notice to prepare their proposals ahead of the February 2026 solicitation release.
Forecast text
OPQ- Drug Sampling and Testing Program
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast